NanoPhoria develops non-viral, nano-delivery systems for cardiovascular treatments, focusing on inhalable biologics.
NanoPhoria has raised $97.8M in total funding. The most recent round was Series A. The last funding was announced in October 2025.
NanoPhoria's investors include CDP Venture Capital, Sofinnova Partners, XGEN Venture, Panakes Partners, EIC Accelerator.
NanoPhoria is headquartered in Milan, Italy.
NanoPhoria develops non-viral, nano-delivery systems for cardiovascular treatments, focusing on inhalable biologics.
NanoPhoria is at the Series A stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"NanoPhoria — Funding & Investors." VCBacked, October 6, 2025, https://www.vcbacked.co/company/nanophoria. Accessed July 19, 2026.
VCBacked. (2025). NanoPhoria — Funding & Investors. Retrieved July 19, 2026, from https://www.vcbacked.co/company/nanophoria
{{cite web |title=NanoPhoria — Funding & Investors |url=https://www.vcbacked.co/company/nanophoria |website=VCBacked |access-date=July 19, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated